By Colin Kellaher
Biotechnology startup Nkarta Therapeutics on Wednesday said it raised $114 million in an oversubscribed Series B funding round at an undisclosed valuation.
Nkarta, which is developing engineered natural killer cell therapies to fight cancer, said new investor Samsara BioCapital led the round.
New investors Amgen Inc.'s (AMGN) Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital and RA Capital Management also participated, joined by existing investors NEA Ventures, SR One and Novo Holdings A/S, Nkarta said.
The South San Francisco, Calif., company, founded in 2015, said it will use the funding to advance multiple programs into clinical trials.
Nkarta, which previously raised $11 million in a Series A financing, also said it expects to complete a manufacturing facility in South San Francisco next year to supply investigational product for its early-stage clinical trials.
Write to Colin Kellaher at email@example.com